Literature DB >> 7520361

Platelet-activating factor mediates an autocrine proliferative loop in the endometrial adenocarcinoma cell line HEC-1A.

M Maggi1, L Bonaccorsi, G Finetti, V Carloni, M Muratori, G Laffi, G Forti, M Serio, E Baldi.   

Abstract

We investigated the synthesis and biological effects of platelet-activating factor (PAF) in the human endometrial cancer cell line HEC-1A. We found that HEC-1A cells actively synthesize and release PAF, as demonstrated by both [3H]acetate incorporation into PAF and gas chromatography-mass spectrometry studies. HEC-1A cells not only synthesize but also respond to PAF. Indeed, in fura-2-loaded cells, PAF stimulates [Ca2+]i increase with a median effective concentration of 5.6 nM. Furthermore, PAF induces a time-dependent expression increase of the nuclear protooncogene c-fos with a median effective concentration of 130 nM and stimulates DNA synthesis (median effective concentration, 700 nM). All of these effects are inhibited by the PAF receptor antagonist L659,989. Radioligand binding studies indicated the presence of two populations of PAF receptors with affinity constants in the nanomolar and micromolar range. Since the PAF antagonist per se inhibits DNA synthesis and cell proliferation, we suggest that PAF supports an autocrine growth circuit in HEC-1A cells. On the contrary, in the uterine leiomyosarcoma cell line SK-UT-1, which does not express specific binding sites for PAF, neither this phospholipid nor its receptor antagonist affect DNA synthesis. Our results provide evidence for the existence of an autocrine proliferative loop involving PAF in the endometrial cancer cell line HEC-1A.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520361

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  The effects of an autocrine loop mediated by platelet-activating factor (PAF) in HEC-1A cells are reverted by uteroglobin.

Authors:  Alessandro Peri; Lorella Bonaccorsi; Federica Cioppi; Monica Muratori; Michaela Luconi; Simone Granchi; Mario Maggi; Elisabetta Baldi
Journal:  Hum Cell       Date:  2003-09       Impact factor: 4.174

2.  Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice.

Authors:  Tej Pratap Singh; Barbara Huettner; Harald Koefeler; Gerlinde Mayer; Isabella Bambach; Katrin Wallbrecht; Michael P Schön; Peter Wolf
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis.

Authors:  B Bussolati; L Biancone; P Cassoni; S Russo; M Rola-Pleszczynski; G Montrucchio; G Camussi
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

4.  Platelet-activating factor in cirrhotic liver and hepatocellular carcinoma.

Authors:  Muriel Mathonnet; Bernard Descottes; Denis Valleix; Véronique Truffinet; Francois Labrousse; Yves Denizot
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

5.  Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.

Authors:  Lorella Bonaccorsi; Sara Marchiani; Monica Muratori; Gianni Forti; Elisabetta Baldi
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-16       Impact factor: 4.553

Review 6.  HEC-1 cells.

Authors:  Hiroyuki Kurarmoto; Mieko Hamano; Manami Imai
Journal:  Hum Cell       Date:  2002-06       Impact factor: 4.174

7.  Palliation of bone cancer pain by antagonists of platelet-activating factor receptors.

Authors:  Katsuya Morita; Seiji Shiraishi; Naoyo Motoyama; Tomoya Kitayama; Takashi Kanematsu; Yasuhito Uezono; Toshihiro Dohi
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

8.  Modulation of Tumor-Associated Macrophages (TAM) Phenotype by Platelet-Activating Factor (PAF) Receptor.

Authors:  Ildefonso Alves da Silva Junior; Simone Cardozo Stone; Renata Marques Rossetti; Sonia Jancar; Ana Paula Lepique
Journal:  J Immunol Res       Date:  2017-12-27       Impact factor: 4.818

Review 9.  Platelet activating factor receptor antagonists improve the efficacy of experimental chemo- and radiotherapy.

Authors:  Ildefonso Alves da Silva Junior; Luciana Nogueira de Sousa Andrade; Sonia Jancar; Roger Chammas
Journal:  Clinics (Sao Paulo)       Date:  2018-10-11       Impact factor: 2.365

10.  Platelet-Activating Factor Receptor Ligands Protect Tumor Cells from Radiation-Induced Cell Death.

Authors:  Ildefonso Alves da Silva-Junior; Barbara Dalmaso; Suellen Herbster; Ana Paula Lepique; Sonia Jancar
Journal:  Front Oncol       Date:  2018-02-05       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.